Bile Duct Cancer Market Dynamics, Analysis of Top Leaders, Sustainable CAGR Status, Global Size, Competitive Landscape, Share Overview, Current Trends, and Forecast to 2023

Bile Duct Cancer Market Dynamics, Analysis of Top Leaders, Sustainable CAGR Status, Global Size, Competitive Landscape, Share Overview, Current Trends, and Forecast to 2023

“Bile Duct Cancer Market”
Market Research Future one of the top brands in the market research industry has published a half-cooked research report on “Bile Duct Cancer Market-Global Forecast to 2023”. Research provides analysis of the market size and shares with segmentation, top leaders, CAGR status.

Market Overview:

Bile duct cancer or cholangiocarcinoma is a rare form of cancer occurring due to uncontrolled growth of abnormal cells within the bile ducts, which can affect surrounding healthy tissues and organs like pancreas and can eventually spread to other areas in the body. Bile duct cancer can be diagnosed by imaging tests, blood test, abdominal ultrasound, a biopsy of the affected tissue and other methods.

According to the American cancer society, 30,200 estimated deaths have occurred in U.S in 2017 and 42,220 new cases of intrahepatic bile duct cancer are expected to occur in the U.S. in 2018. The growing prevalence of bile duct cancer is likely to boost the market in the forecast period.

The global bile duct cancer market accounted to USD 154.5 million in 2017 and is forecasted to demonstrate a radial growth by 2018, global Bile Duct market is expected to grow at a CAGR of 9.1% during forecasted period 2018-2023.

Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/4741

Competitive Landscape:

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd
  • Eli Lilly and Company
  • Sanofi
  • Fresenius Kabi AG
  • Mylan N.V.
  • Pfizer Inc
  • Johnson & Johnson
  • Celgene Corporation

In March 2018, Eli Lilly and Company announced the successful completion of its primary phase 3 REACH-2 trial study in trial biomarker selected population for CYRAMZA (ramucirumab), a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC). The trial met its primary and secondary endpoint. This study proves beneficial for the company as CYRAMZA has demonstrated survival benefits in four regressive tumor type and as a single agent in hepatocellular carcinoma.

Segmentation:

  • The global bile duct cancer market is segmented on the basis of types, diagnosis, treatment, and end users.
  • On the basis of types, the market is segmented into intrahepatic, extrahepatic, and others.
  • On the basis of diagnosis, the market is segmented into blood tests, abdominal imaging, surgery, and others. The diagnosis segment by abdominal imaging is sub-segmented into endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), magnetic resonance cholangiopancreatography (MRCP), and others.
  • On the basis of treatment, the market is segmented into chemotherapy, radiotherapy, and others. The chemotherapy segment is sub-segmented into 5-fluorouracil, gemcitabine, cisplatin, and others.
  • On the basis of end users, the market is segmented into hospital &clinics, academic institutes, research organizations, and others.

Regional Analysis:

The American region consisting of North America and South America dominates the global bile duct cancer market. As per the reports published by cholangiocarcinoma foundation in 2017, every year about 6,000 people suffer from bile duct cancer in the United States. The presence of well-established healthcare sector, an increasing number of patients have stimulated the growth of the market in the Americas. 

Europe is the second largest bile duct cancer market owing to increasing incidence of bile duct cancer, advanced in cancer-related discoveries and ongoing innovations for treating cancer in early stages.

The Asia Pacific is the rapidly growing region for the bile duct cancer market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge growth prospects in the market.

The Middle East & Africa has the least share in the global bile duct cancer market due to the presence of poor economy and lack of awareness mainly in Africa region. Majority of the market of this region is held by the Middle East due the presence of developed economies like Saudi Arabia, Kuwait, and Qatar region. Apart from this, the well-developed healthcare sector and huge healthcare expenditure boost the market growth in this region.

Access Full Report and TOC Details @ https://www.marketresearchfuture.com/reports/bile-duct-cancer-market-4741

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/bile-duct-cancer-market-4741